US Patent Issued to Alnylam Pharmaceuticals on Aug. 18 for "Mannan binding lectin serine peptidase 2 (MASP2) IRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,709,751, issued on Aug. 18, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Mannan binding lectin serine peptidase 2 (MASP2) IRNA compositions and methods of use thereof" was invented by James D. Mcininch (Burlington, Mass.) and Anna Borodovsky (Melrose, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the mannan binding lectin serine peptidase 2 gene (MASP2). The invention also relates to methods of using such RNAi agents to inhibit expression of a MASP2 gene and to methods of preventing and treating a MASP2-associated disorders, e.g....